Related Experiment Video

Updated: Sep 18, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Established beta-adrenergic receptor blocking therapy and acute myocardial infarction. A clinical study of risks and

U Dahlström, U Berglund, E Karlsson

    Acta Medica Scandinavica
    |January 1, 1980
    PubMed

    Insights

    Continuing beta-adrenergic receptor blocking drugs during acute myocardial infarction (AMI) did not increase complication risks. However, patients on this therapy experiencing inferior AMI may face a higher risk of sudden death.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Acute myocardial infarction (AMI) management involves assessing risks of ongoing therapies.
    • Beta-adrenergic receptor blocking drugs are commonly used for cardiovascular conditions.

    Purpose of the Study:

    • To evaluate the risks and benefits of continuing beta-adrenergic receptor blocking drugs during AMI.
    • To compare complication rates between patients on and off established beta-blocker therapy.

    Main Methods:

    • A study of 183 consecutive AMI patients (63 on beta-blockers, 120 controls).
    • Collection of detailed patient data including medical history, symptoms, medications, and clinical/laboratory findings.
    • Monitoring for complications such as congestive heart failure, hypotension, AV blocks, and ventricular arrhythmias within the first 12 hours in the CCU.

    Main Results:

    • No significant increase in congestive heart failure, hypotension, AV blocks, or ventricular arrhythmias was observed in the control group compared to the beta-blocker group.
    • A lower incidence of inferior wall infarction was noted in the beta-blocker group, though the reason is unclear.
    • The study suggests continuation of beta-blocker therapy does not elevate immediate post-admission risks.

    Conclusions:

    • Continuation of established beta-adrenergic receptor blocking drugs during AMI appears safe regarding immediate complications.
    • Patients on beta-blocker therapy who develop inferior AMI might be at increased risk for sudden death.
    • Further research is needed to clarify the association between beta-blockers, inferior AMI, and sudden death risk.

    More Related Videos

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

    Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

    Published on: December 16, 2022

    Related Concept Videos

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...